Major Alzheimer’s drug review divides the experts
Cochrane concluded that anti-amyloid drugs produce no clinically meaningful benefit. Some neurologists say the conclusion is correct, but also misleading. Anti-amyloid drugs face a damning verdict — but the newest ones may be different A major new analysis of 17 clinical trials with more than 20,000 participants concluded that the current front line in Alzheimer’s treatment — anti-amyloid drugs — are unlikely to make a significant difference to either the severity of symptoms or extent of cognitive decline. They also appear to raise the risk of brain swelling and bleedi...
